ArticleFuture oncology (London, England)2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Mazyar Shadman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.